Advertisement

Organ and Metabolic Complications: β2-Microglobulin Amyloidosis

  • Juergen Schaeffer
  • Karl-Martin Koch

Abstract

Five years after the initial publication on carpal tunnel syndrome in hemodialysis patients (1), Assenat et al. (2) were the first to point out an association of this syndrome with a local deposition of amyloid. In 1984, Charra et al. (3) reported a correlation of the shoulder pain syndrome in hemodialysis patients with amyloid-positive histology from carpal tunnel surgery, and described the presence of amyloid in synovial tissue. Bardin et al. (4) established amyloidosis as a prominent cause of carpal tunnel syndrome, finger flexor synovitis, and cystic bone radiolucencies, and coined the phrase ‘dialysis amyloidosis’. The existence of a new form of amyloidosis peculiar to long-term hemodialysis patients underlying the amyloid arthropathy was suggested in 1985 (5), but the etiology and biochemical precursor were still unknown (6, 7).

Keywords

Carpal Tunnel Syndrome Carpal Tunnel Nephrol Dial Transplant Carpal Tunnel Surgery Amyloid Arthropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Warren DJ, Otieno LS: Carpal tunnel syndrome in patients on intermittent hemodialysis. Postgrad Med J 51: 450, 1975PubMedGoogle Scholar
  2. 2.
    Assenat H, Calemard E, Charra B, Laurent G, Terret JC, Vanel T: Hemodialyse syndrome du canal carpien et substance amyloide. Nouv Presse Med 9: 1715, 1980PubMedGoogle Scholar
  3. 3.
    Charra B, Calemard E, Uzan M, Terrat JC, Vanel T, Laurent G: Carpal tunnel syndrome, shoulder pain and amyloid deposits in long-term haemodialysis patients. Proc EDTA-ERA 21: 291, 1984Google Scholar
  4. 4.
    Bardin T, Kuntz D, Zingraff J, Voisin MC, Zelmar A, Lansaman J: Synovial amyloidosis in patients undergoing long-term hemodialysis. Arthritis Rheum 28: 1052, 1985PubMedGoogle Scholar
  5. 5.
    Munoz-Gomez J, Bergadá-Barado E, Gómez-Pérez R, Llopart-Buisán E, Subías-Sobrevía E, Rotés-Querol J, Solé-Arqués M: Amyloid arthropathy in patients undergoing periodical haemodialysis for chronic renal failure: a new complication. Ann Rheum Dis 44: 729, 1985PubMedGoogle Scholar
  6. 6.
    Morita T, Suzuki M, Kamimura A, Hirasawa Y: Amyloidosis of a possible new type in patients receiving long-term hemodialysis. Arch Pathol Lab Med 109: 1029, 1985PubMedGoogle Scholar
  7. 7.
    Rowe IF: Editorial: Amyloid arthropathy. Ann Rheum Dis 44: 727, 1985PubMedGoogle Scholar
  8. 8.
    Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T, Cohen AS, Schmid K: A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Com 129: 701, 1985PubMedGoogle Scholar
  9. 9.
    Gejyo F, Odani S, Yamada T, Homma N, Saito H, Suzuki Y, Nakagawa Y, Kobayashi H, Maruyama Y, Hirasawa Y, Suzuki M, Arakawa M: β2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Inl 30: 385, 1986Google Scholar
  10. 10.
    Gorevic PD, Casey TT, Stone WJ, DiRaimondo CR, Prelli FC, Frangione B: Beta2-microglobulin is an amyloidogenic protein in man. J Clin Invest 76: 2425, 1985PubMedGoogle Scholar
  11. 11.
    Bardin T, Zingraff J, Kuntz D, Drüeke T: Dialysis-related amyloidosis. Nephrol Dial Transplant 1: 151, 1986PubMedGoogle Scholar
  12. 12.
    Benz RL, Siegfried JW, Teehan BP: Carpal tunnel syndrome in dialysis patients: comparison between continuous ambulatory peritoneal dialysis and hemodialysis populations. Am J Kid Dis 11: 473, 1988PubMedGoogle Scholar
  13. 13.
    Gagnon RF, Lough JO, Bourgouin PA: Carpal tunnel syndrome and amyloidosis associated with continuous ambulatory peritoneal dialysis. Can Med Assoc J 139: 753, 1988Google Scholar
  14. 14.
    Cornélis F, Bardin T, Faller B, Verger C, Allouache M, Raymond P, Rottembourg J, Tourlière, Benhamou C, Noel LH, Kuntz D: Rheumatic syndromes and β2-microglobulin amyloidosis in patients receiving long-term peritoneal dialysis. Arthritis Rheum 32: 785, 1989PubMedGoogle Scholar
  15. 15.
    Brown E, Soldano L, Hendler E: Dialysis-related amyloidosis during peritoneal dialysis. Trans Am Soc Artif Intern Organs 36: 17, 1990Google Scholar
  16. 16.
    Jadoul M, Noel H, van Ypersele de Strihou C: β2-microglobulin amyloidosis in a patient treated exclusively by continuous ambulatory peritoneal dialysis. Am J Kid Dis 15: 86, 1990PubMedGoogle Scholar
  17. 17.
    Linke RP, Bommer J, Ritz E, Waldherr R, Eulitz M: Amyloid kidney stones of uremic patients consist of beta2-microglobulin fragments. Biochem Biophys Res Comm 136:665, 1986PubMedGoogle Scholar
  18. 18.
    Morinière P, Marie A, El Esper N, Fardellone P, Deramond H, Remond A, Sebert JL, Fournier A: Destructive spondylarthropathy with β2-microglobulin amyloid deposits in a uremic patient before chronic hemodialysis. Nephron 59: 654, 1991PubMedGoogle Scholar
  19. 19.
    Noel LH, Zingraff J, Bardin T, Atienza C, Kuntz D. Drüeke T: Tissue distribution of dialysis arhyloidosis. Clin Nephrol 27: 175, 1987PubMedGoogle Scholar
  20. 20.
    Maher ER, Hamilton Dutoit S, Baillod RA, Sweny P, Moorhead JF: Gastrointestinal complications of dialysis related amyloidosis. Br Med J 297: 265, 1988Google Scholar
  21. 21.
    Arakawa M, Geijo F, Oohara K, Homma N: Systemic deposition of beta-2 microglobulin amyloid. in Dialysis Amyloidosis, edited by Geijo F, Brancaccio D, Bardin T, Milan, Wichtig Editore, 1989, p 11Google Scholar
  22. 22.
    Shinoda T, Komatsu M, Aizawa T, Shirota T, Yamada T, Jhara T, Mizukami E: Intestinal pseudo-obstruction due to dialysis amyloidosis. Clin Nephrol 32: 284, 1989PubMedGoogle Scholar
  23. 23.
    WHO-IUS Nomenclature Sub-Committee: Nomenclature of amyloid and amyloidoses. Bull World Health Org 71: 105, 1993Google Scholar
  24. 24.
    Drüeke T, Zingraff J: Beta-2-microglobulin-related amyloidosis in long-term hemodialysis patients: possible pathogenetic mechanisms. Contr Nephrol 59: 99, 1987Google Scholar
  25. 25.
    Kleinman KS, Coburn JW: Amyloid syndromes associated with hemodialysis. Kidney Int 35: 567, 1989PubMedGoogle Scholar
  26. 26.
    Koch KM: Dialysis-related amyloidosis. Kidney Int 41: 1416, 1992PubMedGoogle Scholar
  27. 27.
    Floege J, Ehlerding G: Beta-2-microglobullin associated amyloidosis (Aβ2M-amyloidosis). Nephron 72: 9, 1996PubMedGoogle Scholar
  28. 28.
    Gravallese EM, Baker N, Lester S, Kay J, Owen WF: Musculoskeletal manifestations in β2-microglobulin amyloidosis. Case discussion. Arthritis Rheum 35: 592, 1992PubMedGoogle Scholar
  29. 29.
    Jain VK, Cestero RVM, Baum J: Carpal tunnel syndrome in patients undergoing hemodialysis. J Am Med Assoc 242: 2868, 1978Google Scholar
  30. 30.
    Halter SK, DeLisa JA, Stolov WC, Scardapane D, Sherrard DJ: Carpal tunnel syndrome in chronic renal dialysis patients. Arch Phys Med Rehabil 62: 197, 1981PubMedGoogle Scholar
  31. 31.
    Delmez JA, Holtmann B, Sicard GA, Goldberg AP, Harter HR: Peripheral nerve entrapment syndromes in chronic hemodialysis patients. Nephron 30: 118, 1982PubMedGoogle Scholar
  32. 32.
    Spertini F, Wauters JP, Poulenas I: Carpal tunnel syndrome: a frequent, invalidating, long-term complication of chronic hemodialysis. Clin Nephrol 21: 98, 1984PubMedGoogle Scholar
  33. 33.
    Corradi M, Paganelli E, Pavesi G: Internal neurolysis and flexor tenosynovectomy: adjuncts in the treatment of chronic median nerve compression at the wrist in hemodialysis patients. Microsurgery 10: 248, 1989PubMedGoogle Scholar
  34. 34.
    Kurer MH, Baillod RA, Madgwick JCA: Musculoskeletal manifestations of amyloidosis. J Bone Joint Surg 73-B: 271, 1991Google Scholar
  35. 35.
    Gejyo F, Homma N, Arakawa M: Carpal tunnel syndrome and β2-microglobulin-related amyloidosis in chronic hemodialysis patients. Blood Purif 6: 125, 1988PubMedGoogle Scholar
  36. 36.
    Rubin LA, Fam AG, Rubenstein J, Campbell J, Saiphoo C: Erosive azotemic osteoarthropathy. Arthritis Rheum 27: 1086, 1984PubMedGoogle Scholar
  37. 37.
    DiRaimondo CR, Casey TT, DiRaimondo CV, Stone WR: Pathologic fractures associated with idiopathic amyloidosis of bone in chronic hemodialysis patients. Nephron 43: 22, 1986PubMedCrossRefGoogle Scholar
  38. 38.
    Vandenbroucke JM, Jadoul M, Maldague B, Huaux JP, Noel H, van Ypersele de Strihou C: Possible role of dialysis membrane characteristics in amyloid osteoarthropathy. Lancet i: 1210, 1986Google Scholar
  39. 39.
    Hurst NP, van den Berg R, Disney A, Alcock M, Albertyn L, Green M, Pascoe V: ‘Dialysis related arthropathy’: a survey of 95 patients receiving chronic haemodialysis with special reference to β2 microglobulin related amyloidosis. Ann Rheum Dis 48: 409, 1989PubMedGoogle Scholar
  40. 40.
    Onishi S, Andress DL, Maloney NA, Coburn JW, Sherrard DJ: Beta2-microglobulin deposition in bone in chronic renal failure. Kidney Int 39: 990, 1991PubMedGoogle Scholar
  41. 41.
    Kuntz D, Naveau B, Bardin T, Drüeke T, Treves R, Dryll A: Destructive spondylarthropathy in hemodialyzed patients. A new syndrome. Arthritis Rheum 27: 369, 1984PubMedGoogle Scholar
  42. 42.
    Sebert JL, Fardellone P, Marie A: Destructive spondylarthropathy in hemodialyzed patients: possible role of amyloidosis. Arthritis Rheum 29: 301, 1986PubMedGoogle Scholar
  43. 43.
    Bindi P, Chanard J: Destructive spondyloarthropathy in dialysis patients: an overview. Nephron 55: 104, 1990PubMedGoogle Scholar
  44. 44.
    Ohashi K, Hara M, Kawai R, Ogura Y, Honda K, Nihei H, Mimura N: Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int 41: 1646, 1992PubMedGoogle Scholar
  45. 45.
    Allain TJ, Stevens PE, Bridges LR, Phillips ME: Dialysis myelopathy: quadriparesis due to extradural amyloid of β2 microglobulin origin. Br Med J 296: 752, 1988Google Scholar
  46. 46.
    Kroner G, Stabler A, Seiderer M, Moran JE, Gurland HJ: β2 Microglobulin-related spondylarthropathy with spinal-cord compression in haemodialysis patients: detection by MRI. Nephrol Dial Transplant 6(Suppl 2): 91, 1991PubMedGoogle Scholar
  47. 47.
    Sethi D, Maher ER, Cary NRB: Dialysis amyloid presenting as acute arthritis. Nephron 30: 73, 1988Google Scholar
  48. 48.
    Campistol JM, Solé M, Munoz-Gómez J, Lopez-Pedret J, Revert L: Systemic involvement of dialysis amyloidosis. Am J Nephrol 10: 389, 1990Google Scholar
  49. 49.
    Takahashi S, Morita T, Koda Y, Murayama H, Hirasawa Y: Gastrointestinal involvement of dialysis-related amyloidosis. Clin Nephrol 30: 168, 1988PubMedGoogle Scholar
  50. 50.
    Watanabe K, Nakamura R, Kano S, Ohtake T, Hosoda Y, Saruta T: Amyloid urinary-tract calculi in patients on chronic dialysis. Nephron 52: 334, 1989PubMedGoogle Scholar
  51. 51.
    Brancaccio D, Gallieni M, Padovese P, Anelli A, Coggi G, Uslenghi C: Dialysis amyloidosis with massive popliteal deposition of beta2-microglobulin amyloid. Lancet ii: 802, 1988Google Scholar
  52. 52.
    Floege J, Brandis A, Nonnast-Daniel B, Westhoff-Bleck M, Tidow G, Linke RP, Koch KM: Subcutaneous amyloid-tumor of beta-2-microglobulin origin in a long-term hemodialysis patient. Nephron 53: 73, 1989PubMedGoogle Scholar
  53. 53.
    Athanasou NA, Ayers H, Rainey AJ, Oliver DO, Duthie RB: Joint and systemic distribution of dialysis amyloidosis. Quart J Med 78: 205, 1991PubMedGoogle Scholar
  54. 54.
    Campistol JM, Solé M, Ferrando J, Palou J, Munoz-Gómez J, López-Pedret J, Revert L: Negativeness of skin biopsy in dialysis amyloidosis. Nephron 48: 259, 1988PubMedGoogle Scholar
  55. 55.
    Varga J, Idelson BA, Felson D, Skinner M, Cohen AS: Lack of amyloid in abdominal fat aspirates from patients undergoing long-term hemodialysis. Arch Int Med 147: 1455, 1987Google Scholar
  56. 56.
    Stein G, Schneider A, Thoss K, Ritz E, Linke RP, Schaefer K, Sperschneider H, Abendroth K, Fünfstück R: Beta-2-microglobulin-derived amyloidosis: onset, distribution and clinical features in 13 hemodialysed patients. Nephron 60: 274, 1992PubMedCrossRefGoogle Scholar
  57. 57.
    van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J, and the Working Party on Dialysis Amyloidosis: Effect of dialysis membrane and patient’s age on signs of dialysis-related amyloidosis. Kidney Int 39: 1012, 1991PubMedGoogle Scholar
  58. 58.
    Maioraca R, Cancarini GC, Brunori G, Camerini C, Manili L: Morbidity and mortality of CAPD and hemodialysis. Kidney Int 43(Suppl 40): S4, 1993Google Scholar
  59. 59.
    Schwarz A, Keller F, Seyfert S, Poll W, Molzahn M, Distler A: Carpal tunnel syndrome: a major complication in long-term hemodialysis patients. Clin Nephrol 22: 133, 1984PubMedGoogle Scholar
  60. 60.
    Haudoin P, Flipo RM, Foissac-Gegoux P, Thevenon A, Pouyol F, Duquesnoy B, Delcambre B: Current aspects of osteoarticular pathology in patients undergoing hemodialysis: study of 80 patients. Part 1. Clinical and radiological analysis. J Rheumatol 14: 780, 1987Google Scholar
  61. 61.
    Charra B, Calemard E, Laurent G: Chronic renal failure treatment duration and mode: their relevance to the late dialysis periarticular syndrome. Blood Purif 6: 117, 1988PubMedGoogle Scholar
  62. 62.
    Floege J, Burchert W, Brandis A, Gielow P, Nonnast-Daniel B, Spindler E, Hundeshagen H, Shaldon S, Koch KM: Imaging of dialysis-related amyloid (AB-amyloid) deposits with 131 I-β2-microglobulin. Kidney Int 38: 1169, 1990PubMedGoogle Scholar
  63. 63.
    Schaeffer J, Ehlerding G, Burchert W, Floege J, Shaldon S, Koch KM: Relationship of scintigraphically proven dialysis-related amyloidosis (DRA) to age and time on hemodialysis (HD). J Am Soc Nephrol 3: 392, 1992Google Scholar
  64. 64.
    Floege J, Schaffer J, Koch KM, Shaldon S: Dialysis related amyloidosis: a disease of chronic retention and inflammation? Kidney Int 42(Suppl 38): S78, 1992Google Scholar
  65. 65.
    Coggi E, Maiorano E, Braidotti P, Dell’Orto P, Viale G: Beta-2 microglobulin amyloidosis in synovial membranes: histopathology, immunocytochemistry and electron microscopy, in Dialysis Amyloidosis, edited by Gejyo F, Brancaccio D, Bardin T, Milan, Wichting Editore, 1989, p 57Google Scholar
  66. 66.
    Homma N, Geyjo F, Isemura M, Arakawa M: Collagen-binding affinity of β2-microglobulin, a preprotein of hemodialysis-associated amyloidosis. Nephron 53: 37, 1989PubMedGoogle Scholar
  67. 67.
    Kisilevsky R, Snow AA: The potential significance of sulphated glycosaminoglycans as a common constituent of all amyloids: or, perhaps amyloid is not a misnomer. Med Hypotheses 26: 231, 1988PubMedGoogle Scholar
  68. 68.
    Gejyo F, Homma N, Suzuki Y, Arakawa M: Serum levels of β2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. (Letter) N Engl J Med 314: 585, 1986PubMedCrossRefGoogle Scholar
  69. 69.
    Linke RP, Hampl H, Barthel-Schwarze S, Eulitz M: β2-microglobulin, different fragments and polymers therof in synovial amyloid in long-term hemodialysis. Biol Chem Hoppe Seyler 368: 137, 1987PubMedGoogle Scholar
  70. 70.
    Connors LH, Shirahama T, Skinner M, Fenves A, Cohen AS: In vitro formation of amyloid fibrils from intact β2-microglobulin. Biochem Biophys Res Comm 131: 1063, 1985PubMedGoogle Scholar
  71. 71.
    Campistol JM, Sole M, Bombi JA, Rodriguez R, Mirapeix E, Munoz-Gomez J, Revert LI: In vitro spontaneous synthesis of beta-2-microglobulin amyloid fibrils in peripheral blood mononuclear cell culture. Am J Pathol 141: 241, 1992PubMedGoogle Scholar
  72. 72.
    Stein G, Schneider A, Thoss K, Ritz E, Schaefer K, Hüller M, Sperschneider H, Marzoll I: β2-microglobulin serum concentration and associated amyloidosis in dialysis patients. Nephrol Dial Transplant 6(Suppl 3): 57, 1991PubMedGoogle Scholar
  73. 73.
    Nachbaur K, Troppmair J, Bieling P, Kotlan B, König P, Huber CH: Cytokines in the control of β2-microglobulin release. In-vitro studies on various hematopoietic cells. Immunobiol 177: 55, 1988Google Scholar
  74. 74.
    Nachbaur K, Troppmair J, Kotlan B, König P, Aulitzky W, Bieling P, Huber CH: Cytokines in the control of β2-microglobulin release. In vivo studies with recombinant interferons and antigens. Immunobiol 177: 66, 1988Google Scholar
  75. 75.
    Lonnemann G, Koch KM, Shaldon S, Dinarello CA: Studies on the ability of hemodialysis membranes to induce, bind and clear human interleukin-1. J Lab Clin Med 112: 16, 1988Google Scholar
  76. 76.
    Haeffner-Cavaillon N, Cavaillon JM, Ciancioni C, Bacle F, Delons S, Katatchkine MD: In vivo induction of interleukin-1 during hemodialysis. Kidney Int 35: 1212, 1989PubMedGoogle Scholar
  77. 77.
    Schindler R, Linnenweber S, Schulze M, Oppermann M, Dinarello CA, Shaldon S, Koch KM: Gene expression of interleukin-1 β during hemodialysis. Kidney Int 43: 712, 1993PubMedGoogle Scholar
  78. 78.
    Schindler R, Lonnemann G, Shaldon S, Koch KM, Dinarello CA: Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney Int 37:85, 1990PubMedGoogle Scholar
  79. 79.
    Laude-Sharp M, Caroff M, Sirnard L, Pusineri C, Kazatchkine MD, Haeffner-Cavaillon N: Induction of IL-1 during hemodialysis: transmembrane passage of intact endotoxins (LPS). Kidney Int 38: 1089, 1990PubMedGoogle Scholar
  80. 80.
    Lonnemann G, Behme TC, Lenzner B, Floege J, Schulze M, Colton CK, Koch KM, Shaldon S: Permeability of dialyzer membranes to TNFalpha-inducing substances derived from water bacteria. Kidney Int 42: 61, 1992PubMedGoogle Scholar
  81. 81.
    Lonnemann G, Koch KM: Pyrogenic reactions. in Replacement of Renal Function by Dialysis, edited by Jacobs C, Kjellstrand C, Koch KM Winchester JM, Dordrecht, Kluwer Academic Publishers, 1996, this volumeGoogle Scholar
  82. 82.
    Campistol JM, Molin R, Bernard D, Rodriguez R, Mirapeix E, Munoz-Gomez J, Revert LI: In vitro synthesis of β2-microglobulin: role of hemodialyisis (HD), dialysis membranes, dialysis-amyloidosis (Aβ2M) and lymphokines. Nephrol Dial Transplant 7: 749, 1992Google Scholar
  83. 83.
    Zingraff J, Beyne P, Urena P, Uzan M, Nguyen Khoa Man, Descamps-Latscha B, Drüeke T: Influence of haemodialy sis membranes on β2-microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 3: 284 1988PubMedGoogle Scholar
  84. 84.
    Paczek L, Schaefer RM, Heidland A: Dialysis membranes inhibit in vitro release of β2-microglobulin from human lymphocytes. Nephron 56: 267, 1990PubMedGoogle Scholar
  85. 85.
    Zaoui PM, Stone WJ, Hakim RM: Effects of dialysis membranes on beta2-microglobulin productioin and cellular expression. Kidney Int 38: 962, 1990PubMedGoogle Scholar
  86. 86.
    Jahn B, Betz M, Deppisch R, Janssen O, Hänsch GM, Ritz E: Stimulation of β2-microglobulin synthesis in lymphocytes after exposure to Cuprophane dialyzer membranes. Kidney Int 40: 285, 1991PubMedGoogle Scholar
  87. 87.
    Honig A, Marsden T, Schad S, Barth C, Pollok M, Baldamus CA: Correlation of β2-microglobulin concentration changes to distribution volume. Int J Artif Organs 11: 459, 1988PubMedGoogle Scholar
  88. 88.
    Floege J, Granolleras C, Merscher S, Eisenbach GM, Deschodt G, Colton CK, Shaldon S, Koch KM: Is the rise in plasma beta-2-microglobulin seen during hemodialysis meaningful? Nephron 51: 6, 1989PubMedGoogle Scholar
  89. 89.
    Vincent C, Revillard JP, Galland M, Traeger J: Serum β2-microglobulin in hemodialyzed patients. Nephron 21: 260, 1978PubMedGoogle Scholar
  90. 90.
    Odell RA, Slowiaczek P, Moran JE, Schindhelm K: Beta 2-microglobulin kinetics in end-stage renal failure. Kidney Int 39: 909, 1991PubMedGoogle Scholar
  91. 91.
    Floege J, Bartsch A, Schulze M, Shaldon S, Koch KM, Smeby LC: Clearance and synthesis rates of β2-microglobulin in hemodialyzed patients and normals. J Lab Clin Med 118: 153, 1991PubMedGoogle Scholar
  92. 92.
    Vincent C, Chanard J, Caudwell V, Lavaud S, Wong T, Revillard JP: Kinetics of l23I-β2-microglobulin turnover in dialyzed patients. Kidney Int 42: 1434, 1992PubMedGoogle Scholar
  93. 93.
    Linke RP, Hampl H, Lobeck H, Rith E, Bommer J, Waldherr R, Eulitz M: Lysine-specific cleavage of β2-microglobulin in amyloid deposits associated with hemodialysis. Kidney Int 36: 675, 1989PubMedGoogle Scholar
  94. 94.
    Hörl WH, Schaefer RM, Heidland A: Effect of different dialyzers on proteinases and proteinase inhibitors during hemodialysis. Am J Nephrol 5: 320, 1985PubMedGoogle Scholar
  95. 95.
    Argiles A, Mourad G, Atkins RC, Mion CM: New insights into the pathogenesis of hemodialysis-related amyloidosis. Semin Dial 3: 149, 1990Google Scholar
  96. 96.
    Campistol JM, Shirahama T, Abraham CR, Rodgers OG, Solé M, Cohen AS, Skinner M: Demonstration of plasma proteinase inhibitors in β2-microglobulin amyloid deposits. Kidney Int 42: 915, 1992PubMedGoogle Scholar
  97. 97.
    Argiles A, Kerr PG, Mion C, Atkins RC: Serum alpha2-macroglobulin levels increase during dialysis independent of the membrane used. Nephrol Dial Transplant 7: 748, 1992Google Scholar
  98. 98.
    Ogawa H, Saito A, Oda O, Nakajima M, Chung TG: Detection of novel beta2-microglobulin in the serum of hemodialysis patients and its amyloidogenic predisposition. Clin Nephrol 30: 158, 1988PubMedGoogle Scholar
  99. 99.
    Odani H, Oyama R, Titani K, Ogawa H, Saito A: Purification and complete amino acid sequence of novel beta2-microglobulin. Biochem Biophys Res Commun 168: 1223, 1990PubMedGoogle Scholar
  100. 100.
    Argiles A, Derancourt J, Jauregui-Adell J, Mion C, Demaille JG: Biochemical demonstration of serum and urinary beta 2-microglobulin in end-stage renal disease patients. Nephrol Dial Transplant 7: 1106, 1992PubMedGoogle Scholar
  101. 101.
    Vincent C, Dennoroy L, Revillard JP: Molecular variants of β2-microglobulin in renal insufficiency. Biochem J 298: 181, 1994PubMedGoogle Scholar
  102. 102.
    Linke RP: Altered β2-microglobulin in the genesis of AB-amyloidosis in uremic patients. Rev Rhum [Engl Ed] 61(Suppl 9): 1, 1994Google Scholar
  103. 103.
    Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T: β2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92: 1243, 1993PubMedGoogle Scholar
  104. 104.
    Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H: Advanced protein glycasolation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 87: 9010, 1990PubMedGoogle Scholar
  105. 105.
    Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A: Cachectin/TNF and IL-1 induced by glucose-modified protein: role in normal tissue remodeling. Science 240: 1546, 1988PubMedGoogle Scholar
  106. 106.
    Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K, Seo H: Involvement of β2-microglobulin modified with advanced glycation end products in the patho-genesis of hemodialysis-associated amyloidosis. J Clin Invest 93: 521, 1994PubMedGoogle Scholar
  107. 107.
    Ueda T: A histological study on the synovial tissue of rat knee joints in the experimental beta2-microglobulin derived amyloidosis. Ryumachi (Japan) 32: 308, 1992Google Scholar
  108. 108.
    Ehlerding G, Floege J, Schäffer J, Drommer W, Koch KM: No evidence for inflammatory or fibrotic synovial changes prior to deposition of dialysis related amyloid. J Am Soc Nephrol 4: 344, 1993Google Scholar
  109. 109.
    Gejyo F, Maruyama H, Teramura T, Kazama J, Ei I, Arahava N: Role of macrophages in β2-microglobulin-related dialysis amyloidosis. Contr Nephrol 112: 97, 1995Google Scholar
  110. 110.
    Ohishi H, Skinner M, Sato AN, Okuyama T, Geyjo F, Kimura A, Cohen AS, Schmid K: Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver, and spleen. Clin Chem 36: 223, 1990Google Scholar
  111. 111.
    Ishii M, Kobayashi H, Chanoki M, Fukai K, Kono T, Hamada T, Muragaki Y, Ooshima A: Possible formation of cutaneous amyloid from degenerative collagen fibers. Acta Derm Venerol 70: 378, 1990PubMedGoogle Scholar
  112. 112.
    Brancaccio D, Garberi A, Ghiggeri GM, Zoni U, Braidotti P, Coggi G: B2M and Kii light chain are putative cofactors in the pathogenesis of dialysis amyloidosis. J Am Soc Nephrol 4: 335, 1993Google Scholar
  113. 113.
    Garcia-Garcia M, Garcia-Valero J, Mourad G, Argiles A: Protein constituents of amyloid deposits in beta2-microglobulin amyloidosis. Rev Rhum [Engl Ed] 61(Suppl 9): 7S, 1994Google Scholar
  114. 114.
    Bommer J, Seelig P, Seelig R, Geerlings W, Bommer G, Ritz E: Determinants of plasma β2Microglobulin concentration: possible relation to membrane biocompatibility. Nephrol Dial Transplant 2: 22, 1987PubMedGoogle Scholar
  115. 115.
    Canaud B, Assounga A, Flavier JL, Slingeneyer A, Aznar R, Robinet-Levy M, Mion C: β-2 microglobulin serum levels in maintenance dialysis — what does is mean? Trans Am Soc Artif Intern Organs 34: 923, 1988Google Scholar
  116. 116.
    Sethi D, Gower PE: Dialysis arthropathy, β2-microglobulin and the effect of dialyser membrane. Nephrol Dial Transplant 3: 768, 1988PubMedGoogle Scholar
  117. 117.
    Hampl H, Lobeck H, Barthel-Schwarze S, Stein H, Eulitz M, Linke RP: Clinical, morphologic, biochemical, and immunohistochemical aspects of dialysis-associated amyloidosis. Trans Am Soc Artif Intern Organs 33: 250, 1987Google Scholar
  118. 118.
    Sole M, Cardesa A, Palacin A, Munoz-Gomez J, Campistol JM: Morphological and immunohistochemical findings in dialysis-related amyloidosis. Appl Pathol 7: 350, 1989PubMedGoogle Scholar
  119. 119.
    Nishi S, Gejyo F, Arakawa M: A histochemical study of hemodialysis related amyloidosis. Acta Med Biol 39(Suppl): 75, 1991Google Scholar
  120. 120.
    Munoz-Gómez J, Gómez-Pérez R, Sole-Arques M, Llopart-Buisán E: Synovial fluid examination for the diagnosis of synovial amyloidosis in patients with chronic renal failure undergoing hemodialysis. Ann Rheum Dis 46: 324, 1987PubMedGoogle Scholar
  121. 121.
    Puchtler H, Sweat F, Levine M: On the binding of congo red by amyloid. J Histochem Cytochem 10: 335, 1962Google Scholar
  122. 122.
    Gejyo F, Homman N. Saito H, Arakawa M: Carpal tunnel sysdrome and beta-2 microglobulin amyloidosis: histological and biochemical aspects. in Dialysis Amyloidosis, edited by Geijo F, Brancaccio D, Bardin T, Milan, Wichtig Editore, 1989, p 35Google Scholar
  123. 123.
    Poznanski AK: The Hand in Radiologic Diagnosis, Ch. 8, Normal variation and congenital anomalies of the wrist, Philadelphia-London-Toronto, WB Saunders, 1974, p 128Google Scholar
  124. 124.
    Miura Y, Ishiyama T, Inomata A, Takeda T, Senma S, Okuyama K, Suzuki Y: Radiolucent bone cysts and the type of dialysis membrane used ip patients undergoing long-term hemodialysis. Nephron 60: 268, 1992PubMedGoogle Scholar
  125. 125.
    Cobby MJ, Adler RS, Swartz R, Mattel W: Dialysis-related amyloid arthropathy: MR findings in four patients. Am Journal Roentgenol 157: 1023, 1991Google Scholar
  126. 126.
    Jadoul M, Malghem J, Vandeberg B, van Ypersele de Strihou C: Ultrasonographic detection of thickened joint capsules and tendons: an early marker of dialysis-related amyloidosis. Nephrol Dial Transplant 5: 727, 1990Google Scholar
  127. 127.
    McMahon LP, Radford J, Dawborn JK: Shoulder ultrasound in dialysis related amyloidosis. Clin Nephrol 35: 227, 1991PubMedGoogle Scholar
  128. 128.
    Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Lazarus JM, Owen WF: Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum 35: 926, 1992PubMedGoogle Scholar
  129. 129.
    Jadoul M, Malghem J, Vande Berg B, Van Ypersele de Strihou C: Ultrasonography of joint capsules and tendons in dialysis-related amyloidosis. Kidney Int 43(Suppl 41): 106, 1993Google Scholar
  130. 130.
    Calemard E, Charra B, Terrat JC, Vanei T, Chazot C, Lauent G, Pracros JP: Hip’s synovial thickness and late dialysis arthropathy. Nephrol Dial Transplant 5: 725, 1990Google Scholar
  131. 131.
    Yood RA, Skinner M, Cohen AS, Lee VW: Soft tissue uptake of bone seeking radionuclide in amyloidosis. J Rheumatatol: 760, 1981Google Scholar
  132. 132.
    Grateau G, Zingraff J, Fauchet M, Mundler O, Raymond P, Berthelot JM, Bardin T, Kuntz D, Drueke T: Radionuclide exploration of dialysis amyloidosis: preliminary experience. Am J Kidney Dis 9: 231, 1988Google Scholar
  133. 133.
    Sethi D, Naunton Morgan TC, Brown EA, Jewkes RF, Gower PE: Technetium-99-labelled methylene diphosphonate uptake scans in patients with dialysis arthropathy. Nephron 54: 202, 1990PubMedGoogle Scholar
  134. 134.
    Hawkins PN, Myers MJ, Epenetos AA, Caspi D, Pepys MB: Specific localization and imaging of mayloid deposits in vivo using 123 I-labelled serum amyloid P component. J Exp Med 167: 903, 1988PubMedGoogle Scholar
  135. 135.
    Hawkins PN, Myers MJ, Lavender JP, Pepys MB: Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet i: 1413, 1988Google Scholar
  136. 136.
    Hawkins PN, Lavender JP, Pepys MB: Evaluation of systemic amyloidosis by scintigraphy with 123 I-labelled serum amyloid P component. N Engl J Med 323: 508, 1990PubMedCrossRefGoogle Scholar
  137. 137.
    Nelson SR, Hawkins PN, Richardson S, Lavender JP, Sethi D, Gower PE, Pugh CW, Winearls CG, Oliver DO, Pepys MB: Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet ii: 335, 1991Google Scholar
  138. 138.
    Zingraff J, Bardin T, Noel LH, Drueke T: Lack of haemodialysis-associated amyloidosis. Lancet ii: 1089, 1991Google Scholar
  139. 139.
    Korzets A, Gafter U, Gal R, Schwartz A, Chagnac A, Weinstein T, Zevin D, Levi J: Hemodialysis associated amyloidosis (HAA) is a systemic disease. J Am Soc Nephrol 4: 362, 1993Google Scholar
  140. 140.
    Duquesnoy B, Flipo RM, Deveaux M, Foissac-Gegoux P, Marchandise X. Imaging of dialysis-related amyloid deposits with iodine-123-labeled serum amyloid P component. Rev Rhum [Engl Ed] 61(Suppl 9): 33S, 1994Google Scholar
  141. 141.
    Floege J, Nonnast-Daniel B, Gielow P, Brandis A, Spindler E, Hundeshagen H, Koch KM, Shaldon S: Specific imaging of dialysis-related amyloid deposits using 13lI-β2-microglobulin. Nephron 51: 444. 1989PubMedGoogle Scholar
  142. 142.
    Schaeffer J, Ehlerding G, Burchert W, Tsobanelis T, Jungheinrich C, Gruetzmacher P, Floege J: Imaging of dialysis-related amyloid (DRA) by 131 I β2-microglobulin scan in CAPD. Nephrol Dial Transplant 7: 752, 1992Google Scholar
  143. 143.
    Ponz E, Piera C, Campistol JM, Lomena F, Deulofeu R, Munoz J, Revert L: Diagnostic imaging of dialysis amyloidosis (D-AM) with 131-β2 microglobulin (β2-M). Preliminary results. Nephrol Dial Transplant 5: 729, 1990Google Scholar
  144. 144.
    Kiyota A, Sugimura T, Yamagami S, Kishimoto T: Specific scintigraphy imaging of dialysis-related amyloid (DRA) deposits using 131I-β2-microglobulin (131I-/β2-M). J Am Soc Nephrol 3: 374, 1992Google Scholar
  145. 145.
    Schäffer J, Burchert W, Floege J, Gielow P, Mahiout A, Nonnast-Daniel B, Shaldon S, Koch KM: Scanning for dialysis related amyloidosis: improved resolution and reduced radiation exposure with 111 Indium-β2-microglobulin. J Am Soc Nephrol 4: 382, 1993Google Scholar
  146. 146.
    Zingraff J, Noel LH, Bardin T, Kuntz D, Dubost C, Drueke T: β2-microglobulin amyloidosis: a stsrnoclavicular joint biopsy study in hemodialysis patients. Clin Nephrol 33: 94, 1990PubMedGoogle Scholar
  147. 147.
    Sethi D, Brown EA, Maini RN, Gower PE. Renal transplantation for dialysis arthropathy. Lancet ii: 448, 1988Google Scholar
  148. 148.
    Jadoul M, Malghem J, Prison Y, Maldague B, van Ypersele de Strihou C: Effect of renal transplantation on the radiological signs of dialysis amyloid osteoarthropathy. Clin Nephrol 32: 194, 1989PubMedGoogle Scholar
  149. 149.
    Sethi D, Brown EA, Cary NRB, Woodrow DF, Gower PE: Persistence of dialysis amyloid after renal transplantation. Am J Nephrol 9: 173, 1988Google Scholar
  150. 150.
    Nelson SR, Sharpstone P, Kingswood JC: Does dialysis-associated amyloid resolve after transplantation ? Nephrol Dial Transplant 8: 369, 1993PubMedGoogle Scholar
  151. 151.
    Kessler M, Netter P, Gaucher A: Outcome of dialysis-associated arthropathy and dialysis-related β2-microglobulin amyloidosis after renal transplantation. Rev Rhum [Engl Ed] 61(Suppl 9:) 93S, 1994Google Scholar
  152. 152.
    Lebail-Darné JL, Bardin T, Zingraff J, Laredo JD, Voisin VC, Kreiss H, Kuntz D: The effect of renal transplantation on dialysis associated arthropathy. Rev Rhum [Engl Ed] 61(Suppl 9): 89S, 1994Google Scholar
  153. 153.
    van Ypersele der Strihou C, Floege J, Jadoul M, Koch KM: Amyloidosis and its relationship to different dialysers. Nephrol Dial Transplant 9(Suppl 2): 156, 1994Google Scholar
  154. 154.
    Floege J, Granolleras C, Deschodt G, Heck M, Baudin G, Branger B, Tournier O, Reinhard B, Eisenbach GM, Smeby LC, Shaldon S: High-flux synthetic versus cellulosic membranes for β2-microglobulin removal during hemodialysis, hemodiafiltration and hemofiltration. Nephrol Dial Transplant 4: 653, 1989PubMedGoogle Scholar
  155. 155.
    Floege J, Smeby L: Dialysis-related amyloidosis and high-flux membranes. Contr Nephrol 96: 124, 1992Google Scholar
  156. 156.
    Canaud B, Assounga A, Kerr P, Aznar R, Mion C: Failure of a daily haemofiltration programme using a highly permeable membrane to return β2-microglobulin concentrations to normal in haemodialysis patients. Nephrol Dial Transplant 7: 924, 1992PubMedGoogle Scholar
  157. 157.
    Drüeke T, Urena P, Man NK, Zingraff J: Membrane transfer, membrane adsorption and possible membrane-induced generation of beta-2-microglobulin. Contr Nephroll 4: 113, 1989Google Scholar
  158. 158.
    Quellhorst E, Schünemann B: Beta-2 amyloidosis and haemofiltration. in Dialysis Amyloidosis, edited by Gejyo F, Brancaccio D, Bardin T, Milan, Wichtig Editore, 1989, p 123Google Scholar
  159. 159.
    Baz M, Durand C, Ragon A, Jaber K, Andrieu D, Merzouk T, Purgus R, Olmer M, Reynier JP, Berland Y: Using ulatrpure water in hemodialysis delays carpal tunnel syndrome. Int J Artif Organs 14: 681, 1991PubMedGoogle Scholar
  160. 160.
    Schindler R, Lonnemann G, Schäffer J, Shaldon S, Koch KM, Krautzig S: The effect of ultrafiltered dlalysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. Nephron 68: 229, 1994PubMedGoogle Scholar
  161. 161.
    Chanard J, Bindi P, Lavaud S, Toupance O, Maheut H, Lacour F: Carpal tunnel syndrome and type of dialysis membrane. Br Med J298: 867, 1989Google Scholar
  162. 162.
    van Ypersele de Strihou C, Jadoul M, Jamart J: Highly permeable and biocompatible membranes. Lancet i: 1415, 1991Google Scholar
  163. 163.
    Brunner FP, Brynger H, Enrich JHH, Fassbinder W, Geerlings W, Rizzoni G, Selwood NH, Tufveson G, Wing AJ: Case control study on dialysis arthropathy: the influence of two different dialysis membranes: data from the EDTA registry. Nephrol Dial Transplant 5: 432, 1990PubMedGoogle Scholar
  164. 164.
    Kessler M, Netter P, Maheut H, Wolf C, Prenat E, Huu TC, Gaucher A: Highly permeable and biocompatible membranes and prevalence of dialysis-associated arthropathy. (Letter) Lancet i: 1092, 1991Google Scholar
  165. 165.
    Simon P, Ang KS, Cavarle Y, Cam G, Catheline M, Genetet N: Does immunodeficiency in uremic patients promote dialysis-related amyloidosis? Int J Artif Organs 11: 102, 1988PubMedGoogle Scholar
  166. 166.
    Furuyoshi S, Matsumura T, Fujimoto T, Yasuda A, Takata S, Tani N, Nakazawa R, Honma N, Gejyo F, Arakawa M: Intensive removal of beta-2-microglobulin with adsorbent column. Nephrol Dial Transplant 7: 750, 1992Google Scholar
  167. 167.
    Bardin T: Low-dose prednisone in dialysis-related amyloid arthropathy. Rev Rhum [Engl Ed] 61(Suppl 9): 97S, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Juergen Schaeffer
    • 1
  • Karl-Martin Koch
    • 2
  1. 1.Division of Nephrology - 6840Hannover Medical SchoolHannoverGermany
  2. 2.Department of NephrologyMedizinische Hochschule HannoverHannover 61Germany

Personalised recommendations